Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2014
May 2014, Vol 5, No 4
May 2014, Vol 5, No 4
Benefits and Risks of Mammography Explored in New Analyses
By
Rosemary Frei, MSc
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
May 2014, Vol 5, No 4
According to a new systematic review of the risks and benefits of breast cancer screening, regular mammography is associated with a 19% reduction in breast cancer mortality, but it is also associated with a 61% cumulative risk of a false-positive result, and approximately 19% of the cases are, in fact, considered overdiagnoses (Pace LE, Keating NL.
JAMA
. 2014;311:1327-1335).
Read Article
New Guidelines Expand Pool of Patients Eligible for Sentinel Node Biopsy
By
Alice Goodman
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
May 2014, Vol 5, No 4
The American Society of Clinical Oncology (ASCO) has issued new guidelines for the use of sentinel node biopsy (SNB) in patients with early-stage breast cancer (Lyman GH, et al.
J Clin Oncol
. 2014;32:1365-1383. The newer version expands the use of SNB to a larger group of patients, based on evidence from 9 randomized trials and 13 cohort studies conducted since 2005, when the first SNB guidelines were published.
Read Article
Up Next for the Center for Medicare and Medicaid Innovation: Cancer
By
Ross D. Margulies, JD, MPH
;
Jayson Slotnik, JD, MPH
Health Policy
,
Policies & Guidelines
May 2014, Vol 5, No 4
In passing the Affordable Care Act (ACA) in 2010, Congress had as one of its central goals the creation of new, innovative ways of paying for and delivering healthcare services. With this goal in mind, the ACA established the Center for Medicare and Medicaid Innovation (CMMI), which is tasked with developing new payment and service delivery models to “demo” and, if successful, to eventually roll out nationwide.
Read Article
Recent HHS Reports Highlight Need to Address Drug Shortages
By
James Cohen, JD
;
Michael Ryan, JD
;
John Warren, JD
Health Policy
,
Policies & Guidelines
May 2014, Vol 5, No 4
In recent years, an increasing number of drug shortages have threatened public health by reducing—if not eliminating—patient access to critical pharmaceuticals.
Read Article
Multigene Testing for Breast Cancer May Be Beneficial
By
Rosemary Frei, MSc
Personalized Medicine
May 2014, Vol 5, No 4
Las Vegas, NV—Researchers are making a compelling case for screening women at high risk for breast cancer for more than
BRCA
mutations. In fact, 4 genetic mutations are well recognized in genetic-based breast cancer, including
CDH1
,
PTEN
,
STK11
, and
TP53
.
Read Article
Simple Blood Test Predicts Response to Enzalutamide in Patients with Prostate Cancer
By
Phoebe Starr
Personalized Medicine
May 2014, Vol 5, No 4
San Diego, CA—A preliminary study from a highly respected group of researchers suggests that a simple blood test for the androgen receptor splice variant-7 (AR-V7) in the AR gene can identify men with castrate-resistant prostate cancer (CRPC) who will not respond to enzalutamide (Xtandi).
Read Article
PD-L1 Expression Potential Biomarker for Response to Immunotherapy with MK-3475
By
Phoebe Starr
Personalized Medicine
May 2014, Vol 5, No 4
San Diego, CA—Two studies, one in melanoma and one in non–small-cell lung cancer (NSCLC), presented at the 2014 American Association for Can-cer Research meeting attempted to correlate response to the anti–programmed cell death (PD)-1 inhibitor MK-3475 with the biomarker PD-L1. The hope is that the level of PD-L1 expression will be a biomarker for the selection of patients for treatment with this new agent.
Read Article
EML4-ALK Fusion Testing and Crizotinib Are Not Cost-Effective in NSCLC
In the Literature
May 2014, Vol 5, No 4
Studies with the tyrosine kinase inhibitor crizotinib (Xalkori) have shown significant improvement in clinical outcomes for the treatment of echinoderm microtubule-associated protein-like 4 and anaplastic lymphoma kinase (EML4-ALK) fusion-positive non–small-cell lung cancer (NSCLC), but researchers recently questioned its cost-effectiveness.
Read Article
Chemotherapy Better Option for Patients with Lung Cancer without EGFR Mutations
In the Literature
May 2014, Vol 5, No 4
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the preferred treatment option for patients with advanced non–small-cell lung cancer (NSCLC) who have tested positive for EGFR mutations, because of better outcomes than conventional chemotherapy.
Read Article
ALK-Positive NSCLC Responds to Ceritinib Treatment
In the Literature
May 2014, Vol 5, No 4
Non–small-cell lung cancer (NSC LC) harboring anaplastic lymphoma kinase (ALK) rearrangement is sensitive to the ALK inhibitor crizotinib (Xalkori). Despite initial responses to crizotinib, resistance ultimately occurs. In preclinical studies, ceritinib (Zykadia), a novel, oral adenosine triphosphate–competitive inhibitor of the ALK tyrosine kinase, has shown greater antitumor potency than crizotinib.
Read Article
Page 2 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma